LRRK2 and Parkinson disease: Furtherly, the LRRK2 inhibitors are considered as a major drug development in treatment of PD patients by elevating levels of cytosolic mtDNA and chronic cGAS signaling (Arru et al., 2016; Weindel et al., 2020).